Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Miricorilant

Inclusion Criteria:

• Non-smoker or light smokers (no more than 5 cigarettes/day or nicotine equivalent)with BMI ≥18.0 and ≤32 kg/m2 and body weight ≥50.0 kg.

• Female participants must be non-childbearing or willing to use an acceptableintra-uterine contraceptive device 4 weeks prior and throughout the study and for 90days after study drug administration.

• Male participants who are sexually active must be willing to use an acceptablecontraceptive method from dosing until at least 90 days after study drugadministration.

• Total abstinence from heterosexual intercourse when this is in line with thepreferred and usual lifestyle of the participant.

• Male participants must be willing to not donate sperm until 90 days following theadministration of the study drug.

• Estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73 m^2 at screening, bythe Modification of Diet in Renal Disease, 4 variable (MDRD4) Equation.

Additional Inclusion Criteria for Control Group Participants Only:

• On a population basis, matched to participants with moderate hepatic impairmentaccording to gender, age (± 10 years), and weight (± 20 %).

• Absence of clinically significant history of neurological, endocrine,cardiovascular, pulmonary, hematological, immunologic, psychiatric,gastrointestinal, renal, hepatic (including cholecystectomy), and metabolic disease.

• Non-clinically significant deviation for laboratory tests results (albumin ≥ thelower limit of normal (LLN), total bilirubin ≤ ULN, aspartate aminotransferase (AST) ≤ upper limit of normal (ULN), alanine aminotransferase (ALT) ≤ ULN, alkalinephosphatase ≤ ULN).

Additional Inclusion Criteria for Participants With Hepatic Impairment Only:

• Participant with stable hepatic impairment (Child-Pugh [CP] class A or B accordingto group)

• Documented parenchymal hepatic disease as evidenced by ultrasonography, computedtomography (CT), magnetic resonance imaging (MRI), or biopsy.

• Participants who have chronic (≥ 6 months) mild or moderate hepatic impairment thathas been clinically stable

• Have hepatic impairment as assessed by a CP classification score: Mild (5-6 points),or Moderate (7-9 points) impaired hepatic function with known medical history ofliver disease.

• Have non-clinically significant findings at physical examination and in clinicallylaboratory evaluations.

• Moderate hepatic impairment participants with nonalcoholic steatohepatitis (NASH)only should have a history or presence of metabolic syndrome or type 2 diabetes,clinical characteristics or prior liver biopsy, ALT ≥ 43 IU/L for men and ≥ 28 IU/Lfor women, and except for participants with prior liver biopsy, participants shouldhave currently or previously one of the following: MRI-iron-corrected T1 (cT1) value > 800 ms, MRI proton density fat fraction (PDFF) liver fat content ≥ 8 % orFibroScan liver stiffness measurement (LSM) ≥ 8.5 kilopascals (kPa).

Exclusion Criteria:

• Clinically significant illness or surgery within 4 weeks prior to dosing.

• Gastrointestinal surgery that interferes with physiological absorption and motilityor gastric bands.

• Clinically significant history or presence of any gastrointestinal pathology, orunresolved gastrointestinal symptoms that can interfere with drug absorption.

• History of suicidal tendency, disposition to seizures, state of confusion, orclinically relevant psychiatric diseases.

• Any medical condition that could be aggravated by glucocorticoid antagonism, and/ormineralocorticoid antagonism, such as autoimmune disease, rheumatic disease,hypotension, or postural hypotension.

• Clinically significant electrocardiogram (ECG) abnormalities or vital signabnormalities at screening

• Acute viral hepatitis in the 6 calendar months before the administration of thestudy drug.

• Positive to Coronavirus disease 2019 (COVID-19) test at screening

• History of Gilbert's syndrome

• Uncontrolled hyperlipidemia

• History of significant drug abuse within 1 year prior to screening or recreationaluse of soft drugs within 1 month or hard drugs within 3 months prior to screening,unless for hepatic impaired participants only, the participants uses any of thesedrugs as prescriptions.

• History of significant alcohol abuse within six months prior to screening or regularuse of alcohol within six months prior to the screening visit.

• Donation of plasma within 7 days prior to dosing. Donation or loss of blood of 50 mLto 499 mL of blood within 30 days, or more than 499 mL within 56 days prior to thedosing.

• Female participants with a positive pregnancy test.

• Participant with a positive alcohol test at screening.

• History of allergic reactions to miricorilant or other related drugs

• Known clinically significant hypersensitivity to any of the ingredients orexcipients of the study drug

• Previous participation in a study with miricorilant administration.

• Participated in a clinical research study involving the administration of aninvestigational or marketed drug or device within 30 days prior to dosing.

• Participants who have taken oral, parenteral, depot or intra-articularglucocorticoids within 12 months prior to study drug administration; or intranasal,topical, or inhaled glucocorticoids within 2 weeks prior to study drugadministration.

• Male participants (including men who have had vasectomies) with a pregnant orlactating partner.

• Breast-feeding female participants

• Inability or difficulty to swallow tablets

• Inability to be venipunctured and/or tolerate catheter venous access.

Additional Exclusion Criteria for Healthy Group (No Hepatic Impairment) Participants Only:

• Previously documented parenchymal hepatic disease evidenced by, for example,ultrasonography, computed tomography, magnetic resonance imaging, or biopsy.

• Any clinically significant abnormality at physical examination, clinicallysignificant abnormal laboratory test results or positive test for HBsAg, HCV, or HIVat screening;

• Participants using medication other than topical products without significantsystemic absorption.

• Participants with a positive urine drug screen at screening.

Additional Exclusion Criteria for Participants with Hepatic Impairment Only:

• Clinically significant unstable medical conditions or clinically significant acuteexacerbation of hepatic disease within 30 days of study drug administration

• Clinically significant abnormalities of laboratory, ECG, or clinical data that wouldpreclude participation in the study

• Presence of chronic kidney disease (CKD).

• Presence of hepatocellular carcinoma or acute hepatic disease from infection or drugtoxicity

• Presence of clinically significant history of lactic acidosis and severehepatomegaly with steatosis

• Presence of active stage 2, 3 or stage 4 hepatic encephalopathy

• Evidence of severe ascites

• Type 1 or uncontrolled Type 2 diabetes

• Presence of surgically-created or transjugular intrahepatic portal systemic shunts.

• Positive test for HIV

• Positive drug screen at screening

• Use of prohibited concomitant medication

• History or clinical evidence of hepatic decompensation or other severe liverimpairment.

• History of liver transplant, or current placement on a liver transplant list.

• For moderate hepatic impairment participants with NASH, a history or clinicalevidence of chronic liver diseases other than nonalcoholic fatty liver disease (NAFLD).

• Weight loss of > 5% total body weight within 3 months prior to screening.